Similar piperacillin/tazobactam target attainment in obese versus nonobese patients despite differences in interstitial tissue fluid pharmacokinetics
D Busse, P Simon, D Petroff, C Dorn, L Schmitt… - Pharmaceutics, 2021 - mdpi.com
Precision dosing of piperacillin/tazobactam in obese patients is compromised by sparse
information on target-site exposure. We aimed to evaluate the appropriateness of current …
information on target-site exposure. We aimed to evaluate the appropriateness of current …
Pharmacokinetics and Pharmacodynamics of High-Dose Piperacillin–Tazobactam in Obese Patients
JJ Veillette, SA Winans, VK Maskiewicz… - European Journal of …, 2021 - Springer
Abstract Background and Objective Standard piperacillin–tazobactam (PT) dosing may be
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …
suboptimal in obesity, but high-dose regimens have not been studied. We prospectively …
Pharmacokinetic analysis of piperacillin administered with tazobactam in critically ill, morbidly obese surgical patients
AW Sturm, N Allen, KD Rafferty, DN Fish… - … : The Journal of …, 2014 - Wiley Online Library
Study Objective To evaluate the steady‐state pharmacokinetic and pharmacodynamic
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …
parameters of piperacillin in morbidly obese, surgical intensive care patients. Design Open …
Population pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese and nonobese patients
EK Chung, SC Cheatham, MR Fleming… - The Journal of …, 2015 - Wiley Online Library
The study objective was to evaluate the population pharmacokinetics and
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in …
Serum piperacillin/tazobactam pharmacokinetics in a morbidly obese individual
D Newman, MH Scheetz, OA Adeyemi… - Annals of …, 2007 - journals.sagepub.com
Objective: To report pharmacokinetic alterations and optimal dosing of piperacillin/
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …
tazobactam in an obese patient. Case Summary: A 39-year-old morbidly obese (weight 167 …
Steady-state pharmacokinetics and pharmacodynamics of piperacillin and tazobactam administered by prolonged infusion in obese patients
SC Cheatham, MR Fleming, DP Healy… - International journal of …, 2013 - Elsevier
The study objective was to evaluate steady-state pharmacokinetics and pharmacodynamics
of piperacillin and tazobactam administered by prolonged infusion in obese patients …
of piperacillin and tazobactam administered by prolonged infusion in obese patients …
[HTML][HTML] Measurement of soft tissue drug concentrations in morbidly obese and non-obese patients–a prospective, parallel group, open-labeled, controlled, phase IV …
P Simon, D Petroff, C Dorn, L Ehmann, C Kloft… - Contemporary Clinical …, 2019 - Elsevier
Background Pharmacokinetic (PK) and pharmacodynamic (PD) data on perioperative
antibiotic prophylaxis or antibiotic therapy are rare in patients suffering from morbid obesity …
antibiotic prophylaxis or antibiotic therapy are rare in patients suffering from morbid obesity …
Repeated Piperacillin-Tazobactam Plasma Concentration Measurements in Severely Obese Versus Nonobese Critically Ill Septic Patients and the Risk of Under–and …
Objective: Obesity and critical illness modify pharmacokinetics of antibiotics, but piperacillin-
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
tazobactam continuous IV infusion pharmacokinetics has been poorly studied in obese …
Ceftolozane/tazobactam dose regimens in severely/morbidly obese patients with complicated intra-abdominal infection or complicated urinary tract infection
AJ Xiao, JA Huntington, J Long, L Caro - International journal of …, 2018 - Elsevier
Ceftolozane/tazobactam is approved for treatment of complicated intra-abdominal infection
(cIAI) and complicated urinary tract infection (cUTI) with renal function-based dose …
(cIAI) and complicated urinary tract infection (cUTI) with renal function-based dose …
Population pharmacokinetics of piperacillin in nonobese, obese, and morbidly obese critically ill patients
The treatment of infections in critically ill obese and morbidly obese patients is challenging
because of the combined physiological changes that result from obesity and critical illness …
because of the combined physiological changes that result from obesity and critical illness …